logo
Plus   Neg
Share
Email

AstraZeneca Names Jose Baselga As Head Of R&D For Oncology - Quick Facts

AstraZeneca PLC (AZN.L,AZN) on Monday announced organisational changes to support scientific innovation and commercial success in the main therapy areas, including the appointment of world-renowned oncology scientist José Baselga to head the company's Research and Development unit for Oncology.

AstraZeneca said it will create therapy area-focused Research and Development or R&D units that are responsible for discovery through to late-stage development - one for BioPharmaceuticals (Cardiovascular, Renal & Metabolism (CVRM) and Respiratory) and one for Oncology - with dynamic resource allocation across the company's pipeline.

AstraZeneca will also create mirrored commercial units - one for BioPharmaceuticals and one for Oncology. The company noted that the creation of the BioPharmaceuticals commercial unit aligns its product strategy and commercial delivery across CVRM and Respiratory.

The R&D units as well as the commercial units will each be represented on the Senior Executive Team of AstraZeneca and report to Chief Executive Officer Pascal Soriot.

The R&D unit for BioPharmaceuticals will be led by Mene Pangalos, who was previously responsible for the company's Innovative Medicines and Early Development Biotech Unit.

The R&D unit for Oncology will be led by Dr. Baselga, a foremost oncology leader with vast experience in the development of innovative cancer therapies, who joins the company today.

Dr. Baselga served as the Physician-in-Chief at Memorial Sloan Kettering Cancer Center or MSK, and Professor of Medicine at Weill Cornell Medical College from 2012 to September 2018.

The commercial unit for BioPharmaceuticals will be led by Ruud Dobber, who was most recently responsible for the company's commercial operations in North America.

The commercial unit for BioPharmaceuticals mirrors the company's existing commercial unit for Oncology, which continues to be led by Dave Fredrickson. The International commercial organisation will remain under the current leadership.

Pascal Soriot, CEO of AstraZeneca, said, "We are entering what we expect will be a period of sustained growth for years to come, which is why we have decided to more closely align our R&D and commercial operations. This new structure will support growth and sharpen the focus on our main therapy areas, speeding up decisions and making us more productive in our mission to bring innovative medicines to patients."

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Shares of STMicroelectronics NV were gaining around 5 percent in Paris and Italy after the Geneva-based semiconductor company on Thursday reported higher earnings and revenues in its fourth quarter, above market estimates. Gross margin, meanwhile, was lower than last year. Further, the company warned on its first-quarter revenues. Consumer goods giant Procter & Gamble Co. on Wednesday reported a 28 percent increase in profit for the second quarter from last year, when results were impacted by a charge related to the U.S. tax reform. Both revenue and core earnings per share for the quarter beat analysts' estimates. Looking ahead, the company affirmed its outlook for fiscal 2019 earnings. LSEG Technology, London Stock Exchange Group's technology solutions provider, said it has been selected by Atom Group, a fintech company focused on blockchain technology and emerging digital assets, to power its new Hong Kong-based digital asset exchange AAX. The new digital exchange, which is expected to launch in the first half of fiscal 2019, will use LSEG's Millennium Exchange matching engine.
Follow RTT